.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Retinopathy of prematurity (ROP) remains a significant cause of childhood blindness worldwide. Current treatments primarily rely on anti-VEGF agents, which occasionally produce off-target effects. Consequently, researchers are exploring alternative biological pathways to target retinal pathological neovascularization. A recent study suggests that the dopaminergic system plays a critical role in regulating abnormal vessel growth in the eye.
Specifically, the study utilized an oxygen-induced retinopathy (OIR) mouse model to understand the role of dopamine. Researchers found that OIR leads to a distinct dopaminergic deficiency. This deficiency impairs the activity of dopamine D2 receptors (Drd2) located on Müller cells. Moreover, integrated single-cell RNA sequencing revealed that Drd2-mediated signaling governs the biosynthesis of hypoxia-inducible factor alpha. Therefore, impaired Drd2 activity directly contributes to the progression of ROP by allowing growth factors to proliferate unchecked.
The investigation examined various dopamine receptor agonists and antagonists to determine their therapeutic potential. Specifically, apomorphine, a non-selective agonist, effectively inhibited vessel proliferation. Furthermore, Müller cell-specific Drd2 knockout mice exhibited worsened outcomes, confirming the protective role of these receptors. Additionally, the study showed that restoring Drd2 signaling reduces vascular endothelial growth factor A (VEGF-A) levels. This finding suggests that dopaminergic agents might complement current anti-VEGF therapies in the future.
In addition to therapeutic potential, this research highlights the importance of Müller cells in retinal health. These cells act as mediators between neuronal activity and vascular stability. Consequently, understanding their interaction with dopamine provides a foundation for future clinical trials. Scientists hope that these insights will lead to more consistent outcomes for premature infants at risk of blindness.
Dopamine acts as a neuromodulator that helps regulate retinal vascular development. A deficiency in dopamine or its receptors can trigger the uncontrolled growth of blood vessels, which leads to vision loss in conditions like ROP.
While effective, anti-VEGF agents can have variable efficacy and may cause off-target effects in the developing eye and systemic circulation. Researchers are looking for more specific targets, such as Drd2 receptors, to improve treatment safety.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research identifies that dopamine deficiency and impaired Drd2 signaling in Müller cells drive pathological angiogenesis in retinopathy of prematurity....
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
